홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.0
  1. 홈
  2. /화합물

An inositol

HCID 892
새 노트새 반응견적 요청하기
인쇄 미리보기
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
38876-99-2
표준 SMILES
OC1C(O)C(O)C(O)C(O)C1O
InChIKey
CDAISMWEOUEBRE-UHFFFAOYSA-N
분자식
C6H12O6
평균 분자량
180.16 g/mol
단동위원소 질량
180.0633881

개요

Myo-inositol is an inositol having myo- configuration. It has a role as a member of compatible osmolytes, a nutrient, an EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor, a mouse metabolite, a Saccharomyces cerevisiae metabolite, an Escherichia coli metabolite, a human metabolite and a Daphnia magna metabolite.

이름 및 식별자

우선 이름
An inositol
IUPAC
cyclohexane-1,2,3,4,5,6-hexol
영어명
1L-chiro-Inositol
분자식
C6H12O6
분자량
180.16

이름 및 동의어

an inositolRefChem:1076961inositolScyllo-inositolmyo-inositolMuco-Inositolepi-InositolAllo-inositolD-chiro-Inositoli-Inositol87-89-8meso-Inositol
이름 더 보기
643-12-91D-Chiro-inositolNeo-inositol488-59-5D-(+)-chiro-Inositolcis-Inositol1L-Chiro-inositol6917-35-7

데이터베이스 식별자

CAS
38876-99-2、488-54-0、488-55-1、488-58-4、488-59-5、551-72-4、576-63-6、643-10-7、643-12-9、6917-35-7、87-89-8
PubChem CID
892
DTXSID
DTXSID30110000
ChEMBL
CHEMBL1231671、CHEMBL1950780、CHEMBL278373、CHEMBL3976780
ChEBI
CHEBI:17268
UNII
1VS4X81277、4661D3JP8D、4L6452S749、587A93P465、63GQX5QW03、6R79WV4R10、8LQ63P85IC、9O6Y5O4P9W、M94176HJ2F、R1Y9F3N15A
EC Number
207-681-5、209-000-7、211-393-5、211-394-0
Nikkaji
J101.888D、J101.889B、J101.890F、J101.891D、J101.892B、J4.282J、J522.945F、J9.771C、J92.778C

물성

구조 계산 물성

XLogP
-3.7
극성 표면적
121 Ų
수소 결합 공여자 수
6
수소 결합 수용자 수
6
회전 가능 결합 수
0
무거운 원자 수
12
형식 전하
0
복잡도
104

실험 및 물리화학적 성질

DrugsPharmaceuticals -> Listed in ZINC15
CosmeticsHair conditioning; Humectant; Antistatic
Animal DrugsPharmaceuticals -> UK Veterinary Medicines Directorate List
Collision Cross Section · 5건

131.3 Ų [M-H]- [CCS Type: DT; Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]

128.61 Ų [M-H]- [CCS Type: DT; Method: single field calibrated with Agilent tune mix (Agilent)]

144.27 Ų [M-H]- [CCS Type: DT; Method: stepped-field]

138.63 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

148.7 Ų [M+Na]+

물리화학적 성질

끓는 점
291.3 · 291.3±40.0 °C(Predicted)
밀도
2.038 · 2.038±0.06 g/cm3(Predicted)
산도 계수 (pKa)
12.63 · 12.63±0.70(Predicted)

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 6건

Warning

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 38 reports by companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

This chemical does not meet GHS hazard criteria for 100% (4 of 4) of all reports.

Not Classified

유해성 정보

Regulatory Information · 6건

neo-Inositol: Does not have an individual approval but may be used under an appropriate group standard

muco-Inositol: Does not have an individual approval but may be used under an appropriate group standard

L-chiro-Inositol: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

cis-Inositol: Does not have an individual approval but may be used under an appropriate group standard

allo-Inositol: Does not have an individual approval but may be used under an appropriate group standard

D-chiro-Inositol: Does not have an individual approval but may be used under an appropriate group standard

Hazard Classes and Categories · 2건

Skin Irrit. 2 (100%)

Not Classified

화학 및 산업

약리 정보

Protein BindingIt is thought that inositol can be found bound to plasma proteins.
Pharmacodynamics · 1건

Inositol can stimulate glucose uptake in skeletal muscle cells which allows the decrease in blood sugar levels. This effect is later seen as a reduction in urine glucose concentration and indicates a decrease in high blood sugar levels. In PCOS, the administration of inositol has produced the remission of symptoms as well as a reduction in male hormone secretion, a regulation of the cholesterol level, and a more efficient fat breakdown which allow to a significant reduction on body mass and appetite. In the cases of infertility, inositol has been proven to increase sperm count and motility, as well as increase the overall quality of oocytes and embryos. In the brain, inositol has been shown to produce an increase in serotonin receptor sensitivity. This activity produces an increase in GABA release. Some of the effects observed in the brain produced a relief in symptoms of anxiety and obsessive-compulsive disorders. In high doses, it has been shown to even reduce panic attacks. In cancer research, inositol has gained interest as it can act as an antioxidant, anti-inflammatory and it seems to enhance immune properties.

Mechanism of Action · 1건

The mechanism of action of inositol in brain disorders is not fully understood but it is thought that it may be involved in neurotransmitter synthesis and it is a precursor to the phosphatidylinositol cycle. The change that occurs in the cycle simulates when the postsynaptic receptor is activated but without activating the receptor. This activity provokes a fake activation which regulated the activity of monoamines and other neurotransmitters. Reports have shown that insulin resistance plays a key role in the clinical development of PCOS. The presence of hyperinsulinemia can induce an excess in androgen production by stimulating ovaries to produce androgens and by reducing the sex hormone binding globulin serum levels. One of the mechanisms of insulin deficiency is thought to be related to a deficiency in inositol in the inositolphosphoglycans. The administration of inositol allows it to act as a direct messenger of the insulin signaling and improves glucose tissue uptake. This mechanism is extrapolated to its functions in diabetes treatment, metabolic syndrome, and weight loss. In cancer, the mechanism of action of inositol is not fully understood. It is hypothesized that the administration of inositol increases the level of lower-phosphate inositol phosphates why can affect cycle regulation, growth, and differentiation of malignant cells. On the other hand, the formation of inositol hexaphosphate after administration of inositol presents antioxidant characteristics by the chelation of ferric ions and suppression of hydroxyl radicals.

관련 반응

27건
반응 기록 만들기
HRID 6617 반응식
HRID 6617생성물로uspto-grants-2006_08
HRID 20720 반응식
HRID 20720생성물로uspto-grants-2010_06
HRID 20721 반응식
HRID 20721생성물로uspto-grants-2010_06
HRID 161509 반응식
HRID 161509반응물로Training data from https://doi.org/10.1039/C8SC04228D (9/10)
HRID 339163 반응식
HRID 339163반응물로uspto-grants-2014_11
HRID 353024 반응식
HRID 353024반응물로uspto-grants-2004_06
HRID 840522 반응식
HRID 840522반응물로uspto-grants-2002_04
HRID 1019480 반응식
HRID 1019480생성물로uspto-grants-2014_05
1 / 4 페이지

화합물 노트

불러오는 중…

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
더보기
새 노트새 반응견적 요청하기
Biological Half-LifeThe pharmacokinetic profile of inositol was studied in preterm infants and the estimated elimination half-life was reported to be of 5.22 hours.
Metabolism/Metabolites · 1건

It is thought that inositol is metabolized to phosphoinositol and then converted to phosphatylinositol-4,5-biphosphate which is a precursor of the second-messenger molecules. Inositol can be transformed to D-chiro-inositol via the actions of an epimerase. The normal modifications to inositol structure seem to be between all the different isomers.

Absorption, Distribution and Excretion · 4건

Inositol is absorbed from the small intestine. In patients with inositol deficiency, the maximal plasma concentration after oral administration of inositol is registered to be of 4 hours. Inositol is taken up by the tissues via sodium-dependent inositol co-transporter which also mediates glucose uptake. Oral ingestion of inositol is registered to generate a maximal plasma concentration of 36-45 mcg.

Most of the administered dose is excreted in urine.

The pharmacokinetic profile of inositol was studied in preterm infants and the estimated volume of distribution was reported to be 0.5115 L/kg.

The pharmacokinetic profile of inositol was studied in preterm infants and the estimated clearance rate was reported to be 0.0679 L.kg/h.

용도 및 제조

Use ClassificationCosmetics -> Hair conditioning; Humectant; Antistatic

상·하류 제품 정보

하류 제품

피틱산